DRG anticipates the next ten years to be an exciting time in the hemophilia space, as the number of treatment options grow for patients with, and without, inhibitors. The hemophilia A pipeline is diverse, both in terms of technology type and administration route, and we are witnessing a shift in R&D emphasis; there is growing interest in non-factor treatment approaches to restore coagulation. Examples include the launch of Roche/Chugai’s bispecific antibody Hemlibra, and the development of gene therapies, such as Biomarin’s BMN 270, and the anti-TPFI drug class, with agents like Novo Nordisk’s concizumab. Despite novel non-factor hemophilia agents forecast to launch, DRG expects the high demand for factor concentrates to persist. We anticipate the factor concentrate market will remain highly competitive, and pipeline agents are looking to further evolve this treatment approach.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
United States, EU5, Japan
PRIMARY RESEARCH INFO
20 country-specific interviews with thought-leading hematologists, specializing in hemophilia. Supported by survey data collected for this and other DRG research
Alnylam, Aptevo, Bayer, Biomarin, Bioverativ, Chugai, CSL Behring, Dimension, Novo Nordisk, Octapharma, OPKO, Pfizer, Roche, Sangamo, Sanofi, Shire, Spark, uniQure
Advate, Adynovate/Adynovi, Afstyla, Alprolix, AMT-061, Benefix, BMN 270, concizumab, DTX 201, Eloctate/Elocta, FEIBA, fitusiran, Helixate, Hemlibra, Idelvion, Ixinity, Kogenate, Kovaltry/Iblias, N8-GP, NovoEight, NovoSeven, Nuwiq, OPK88005, PF-06741086, Rebinyn/Refixia, ReFacto/Xyntha, Rixubis, SB-525, SB-FIX, SPK-8011, SPK-9001